title: 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction.
abstract: 20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 metabolite of arachidonic acid that regulates vascular function and sodium homeostasis. Studies showing an association between 20-HETE excretion, raised BMI, and oxidative stress suggest that 20-HETE may be important in the development of cardiovascular disease in the metabolic syndrome (MetS). We investigated whether 20-HETE and F(2)-isoprostanes (markers of oxidative stress) were altered in the MetS before and after weight reduction. A case-controlled comparison of 30 participants with the MetS and matched controls showed that plasma and urinary 20-HETE and F(2)-isoprostanes were significantly elevated in the MetS group. There was a significant gender x group interaction such that women with the MetS had higher urinary 20-HETE and F(2)-isoprostanes compared to controls (p<0.0001). In a randomized controlled trial, 42 participants with the MetS were assigned to 16 weeks of weight maintenance or a 12-week weight-loss program followed by 4 weeks weight stabilization. Relative to the weight-maintenance group, a 4-kg loss in weight resulted in a 2-mm Hg fall in blood pressure (BP) but did not alter urinary or plasma 20-HETE or F(2)-isoprostanes. 20-HETE and oxidative stress may be important mediators of cardiovascular disease risk in the MetS. Although a 4% reduction in body weight reduced BP, there were no changes in plasma or urinary 20-HETE or F(2)-isoprostanes.
authors.affiliation: University of Western Australia School of Medicine and Pharmacology, Royal Perth Hospital, Perth, WA 6000, Australia.
authors.forename: I-Jung
authors.initials: IJ
authors.lastname: Tsai
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Croft
authors.forename: Trevor A
authors.initials: TA
authors.lastname: Mori
authors.forename: John R
authors.initials: JR
authors.lastname: Falck
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Beilin
authors.forename: Ian B
authors.initials: IB
authors.lastname: Puddey
authors.forename: Anne E
authors.initials: AE
authors.lastname: Barden
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood / Q000652:urine; D018660:Blood Pressure Monitoring, Ambulatory; D002318:Cardiovascular Diseases / Q000209:etiology; D028441:F2-Isoprostanes / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000097:blood / Q000652:urine; D006973:Hypertension; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000503:physiopathology / Q000652:urine*; D008875:Middle Aged; D009765:Obesity; D018384:Oxidative Stress / Q000502:physiology; D012307:Risk Factors; D015431:Weight Loss / Q000502:physiology*
chemical_list: D015415:Biomarkers; D028441:F2-Isoprostanes; D006893:Hydroxyeicosatetraenoic Acids; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid